An improved understanding of disease pathogenesis leads to identification of novel therapeutic targets. From a pharmacologic point of view, these can be addressed by small chemical compounds, so-called biologicals (eg, mAbs and recombinant proteins), or by a rather new class of molecule based on the antisense concept. Recently, a new wave of clinical studies exploring antisense strategies is evolving. In addition to cancer, they include predominantly trials on infectious and noninfectious diseases, such as chronic inflammatory and metabolic conditions. This article, based on a systematic PubMed literature search, highlights recent developments in this emerging field.
- Potaczek, D. P.; Garn, H.; Unger, S. D.; Renz, H.
Keywords
- Eye Diseases/drug therapy
- Humans
- Inflammation/drug therapy
- Metabolic Diseases/drug therapy
- Oligonucleotides, Antisense/pharmacology/*therapeutic use
- Virus Diseases/drug therapy
- Clinical trial
- DNAzyme
- antisense
- small interfering RNA
- therapy
